☆ 4.7 Letter

Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma

BLOOD (2015)

Journal

BLOOD

Volume 125, Issue 21, Pages 3357-3359

Publisher

AMER SOC HEMATOLOGY

DOI: 10.1182/blood-2015-03-633156

Keywords

-

Categories

Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.